However, based on dose response studies, these investigators concluded that circulating FGF21 is increased during obesity to maintain insulin sensitivity, and not due to “FGF21 resistance”5. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.